MAGEA3 and cancer: This is relevant considering that a TCR directed against another cancer-testis antigen, MAGE-A3, previously generated in our laboratory [45] induced tumor regression but also severe neurotoxicity in a Phase I clinical trial of adoptive immunotherapy.